Korean drug company Samsung Bioepis has filed a lawsuit seeking to invalidate German drug company Fresenius Kadi’s patent for a biosimilar of blockbuster arthritis drug Humira.
Korean drug company Samsung Bioepis has filed a lawsuit seeking to invalidate German drug company Fresenius Kadi’s patent for a biosimilar of blockbuster arthritis drug Humira.
For information on rights and reprints, contact subscriptions@lawyerly.com.au